Source: Annual Congress 2009 - Prognosis and comorbidities in COPD
Disease area: Airway diseases

Abstract

Introduction: Published studies demonstrated that high doses of inhaled corticosteroids may increase the risk of osteopenia/osteoporosis. Purpose: to assess the osteoporosis risk associated with chronic corticoid inhalation.
Materials and methods: we studied 20 COPD patients, treated with inhalatory corticoids. We assessed the ventilation parameters, body composition and bone mineral density (BMD) - with the DEXA method (dual energy X-ray absorptiometry). The subjects were classified, according to their BMD, into 3 diagnosis categories: osteoporosis (T score less than -2,5, 12 subjects), osteopenia (T score between -1 and -2,5, 7 subjects) and normopenia (T score higher than -1, 1 subject).
Results: the body fat percentage (F and %F) was lower in the osteoporosis group than in the osteopenia group, but this difference was not statistically significant. Vital capacity (VC) and forced expiratory volume (FEV1) were lower in the osteoporotic patients, compared to the osteopenic ones. There were no significant differences between the corticotherapy duration in the two groups and we found no significant correlation between this duration and BMD.
Conclusions: apparently, chronic corticoid inhalation does not significantly influence the BMD, but given the small number of patients in our study, these results are not definite and further research is needed.

Rating:

Share or cite this content

Citations should be made in the following way:
V. Zbranca, V. Mocanu, L. Enache, E. Zbranca (Iasi, Romania). Osteoporosis risk associated with chronic corticoid inhalation therapy in patients with COPD. Eur Respir J 2009; 34: Suppl. 53, 521

Member's Comments

No comment yet.

Related content which might interest you: Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Compliance with nebulized therapy in patients with chronic lung disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study Source: Eur Respir J, 57 (2) 2000515; 10.1183/13993003.00515-2020 Year: 2021 Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001 Budesonide is not associated with increased risk of pneumonia in COPD patients Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009 Statin use is associated with reduced mortality in COPD Source: Eur Respir J 2007; 29: 279-283 Year: 2007 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Source: Eur Respir J 2009; 33: 282-288 Year: 2009 Impact of inhaled corticosteroids in patients with cardiovascular disease Source: Eur Respir Monogr 2020; 88: 251-263 Year: 2020 Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Changes in inhalation therapy after combined assessment of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Use of inhaled corticosteroids and the risk of depressive symptoms in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Lung disease burden and management Year: 2021 Telithromycin is effective in the treatment of patients with acute exacerbations of chronic bronchitis and risk factors for morbidity Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 The risk of hyperkalemia in COPD and asthma patients Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010